Tamoxifen and contralateral breast cancer

Journal of the American College of Surgeons

Volumn 188, Issue 6, 1999, Pages 678-683

  O'Regan, Ruth ^a   Jordan, V Craig ^a   Gradishar, William J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NW Univ Feinberg School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HORMONAL REGULATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0032991325     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(99)00057-5     Document Type: Review

References (38)

1. Boring C, Squire T, Tong T, et al. Cancer statistics CA Cancer J Clin 1994;44:7-26.
2. Mason BH, Holdaway IM, Benton NM, et al. Detection of contralateral breast cancer by mammography in women with previous breast cancer and the impact of endocrine therapy. NZ Med J 1993;106:23-25.
3. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83: 1450-1459.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early stage breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
6. Fisher B, Redmond C, and others from the National Surgical Adjuvant Breast and Bowel Project. Systemic therapy in node-negative patients: updated findings from the NSABP clinical trials. J Natl Cancer Inst Monogr 1992;1:105-116.
7. Rutquist LE, Johansson H, Signomkloa T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-651.
8. Current Trials Working Party of the Cancer Research Campaign Breast Cancer trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-1839.
9. Andersson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy in early breast cancer. Acta Oncol 1992;31:259-263.
10. Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1997:171-175.
11. NATO. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years by "Nolvadex" Adjuvant Trial Organisation. Br J Cancer 1988;57: 608-611.
12. Ribeiro G, Swindell R. The Christie Hospital Adjuvant Tamoxifen Trial. J Natl Cancer Inst Monogr 1992;11:121-125.
13. Ingle JN, Everson LK, Wieand HS, et al. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 1988;6:1388-1396.
14. Ingle JN, Everson LK, Wieand HS, et al. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer 1989;63: 1257-1264.
15. Ryden S, Ferno M, Moller T, et al. Longterm effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31:271-274.
16. Prithard KI, Meakin JW, Boyd NF. Adjuvant tamoxifen in post-menopausal women with axillary node-positive breast cancer: an update. In: Salmon SE, ed. Adjuvant Therapy of Cancer V. New York: Grune and Stratton; 1987: 391-400.
17. Ludwig Breast Cancer Study Group. Randomized trial of chemoendocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984;1:1256-1260.
18. Castiglione M, Gelber RD, Goldhirsch A, for the International Breast Cancer Study Group. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol 1990;8:519-526.
19. Boccardo F, Rubagotti A, Amoroso D, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemohormone Therapy Cooperative Group) Trial. Eur J Cancer 1992; 28:673-680.
20. Palshof T, Carstensen B, Mouridsen HT, et al. Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Endo Rel Cancer 1985;17[Suppl]:43-50.
21. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 1993; 11:29-35.
22. Holt S, Bradley S, De Sousa BA, et al. A randomized controlled trial of adjuvant hormono-chemotherapy in stage II breast cancer. Eur J Surg Oncol 1988;14:663-667.
23. Stewart HJ for the Scottish Cancer Trials Breast Group. The Scottish Trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr 1992;11:117-120.
24. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
25. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927-934.
26. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-613.
27. Welsch CW, Goodrich-Smith M, Brown CK, et al. Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma radiation-induced mammary tumors in female Sprague-Dawley rats. Eur J Cancer 1981;17:1255-1258.
28. Gottardis MM, Jordan VC. The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4024.
29. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976;12:419-424.
30. Jordan VC, Allen KE. Evaluation of the antitumor activity of the non-steroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980;16:239-251.
31. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res Treat 1983:3[Suppl]:S73-86.
32. Jordan VC, Lababidi MK, Mirecki DM. Anti-oestrogenic and anti-tumor properties of prolonged tamoxifen therapy in C3H/ OUJ mice. Eur J Cancer 1990;26:718-721.
33. Jordan VC, Lababidi MK, Langan-Fahey SM. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-496.
34. Hahnel R, Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas. Breast Cancer Res Treat 1985;5:155-163.
35. Gogas J, Markopoulos CH, Skandalakis P, et al. Bilateral breast cancer. Am Surg 1993;59:733-735.
36. International Agency for Research in Cancer (IARC): Tamoxifen. IARC Monographs 1996;66:274-365.
37. Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Proc ASCO 1998; Philadelphia: WB Saunders; Abs 3:2a.
38. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ∼12,000 postmenopausal women. Proc ASCO 1998;Abs 466;122a.